This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Halyard Health (HYH) Announces Positive Data on COOLIEF
by Zacks Equity Research
Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.
Surmodics Receives FDA's Approval for PTA Balloon Catheter
by Zacks Equity Research
Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
by Zacks Equity Research
Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.
Myriad Genetics Presents Favorable riskScore Test Data
by Zacks Equity Research
Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.
McKesson to Gain From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.
Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet
by Zacks Equity Research
Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.
Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare
by Zacks Equity Research
Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.
NuVasive Launches Breakthrough in MIS Surgery -- LessRay
by Zacks Equity Research
NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.
Genomic Health Ties up With Biocartis, Boosts Oncotype DX
by Zacks Equity Research
Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.
Fresenius Medical Opens Manufacturing Plant in Malaysia
by Zacks Equity Research
Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.
Amedisys Rides High on Strong Prospects Amid Margin Woes
by Zacks Equity Research
Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
IDEXX Laboratories Rides High on Strong CAG, Global Growth
by Zacks Equity Research
IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.
Medtronic Launches StealthStation Technology, Expands in ENT
by Zacks Equity Research
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.
CVS Health Gains on Pharmacy Services, Retail Remains a Drag
by Zacks Equity Research
CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.
Quotient Limited (QTNT) in Focus: Stock Moves 30.3% Higher
by Zacks Equity Research
Quotient Limited (QTNT) saw its shares rise over 30% on the day.
Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag
by Zacks Equity Research
Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.
Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.
Why the Earnings Streak Will Continue for Edwards Lifesciences (EW)
by Zacks Equity Research
Edwards Lifesciences (EW) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Zimmer Biomet (ZBH) Launches Persona Partial Knee System
by Zacks Equity Research
Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.
Cooper Companies Buys Teva's PARAGARD Intrauterine Platform
by Zacks Equity Research
Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.
Henry Schein MicroMD Software Gets ONC-Health IT Certificate
by Zacks Equity Research
Henry Schein's (HSIC) MicroMD receives ONC-Health IT Certificate from Drummond Group, boosting the company's technology and value-added service business.